The immunity they have from being sued is another one. No need to spend millions or billions paying off anyone harmed by the drug.- Cole on the financial incentive for pharmaceutical companies: “It’ll be recurring fountain of revenue. It might not be that much initially, but it’ll be recurring -- if they can -- if they can get every person required at an annual vaccine, that is a recurring return of money going into their company.”